You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSecobarbital
Accession NumberDB00418  (APRD00497)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionSecobarbital (marketed by Eli Lilly and Company under the brand names Seconal® and Tuinal) is a barbiturate derivative drug. It possesses anaesthetic, anticonvulsant, sedative and hypnotic properties. In the United Kingdom, it was known as Quinalbarbitone.
Structure
Thumb
Synonyms
(+-)-Secobarbital
(±)-secobarbital
5-(1-Methylbutyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Allyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-allyl-5-(1-methylbutyl)barbituric acid
5-Allyl-5-(1-methylbutyl)pyrimidine-2,4,6(1H,3H,5H)-trione
Quinalbarbitone
Secobarbitalum
Secobarbitone
Seconal
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-secobarb 100mgcapsule100 mgoralNovopharm Limited1967-12-312005-08-10Canada
Seconal Sodium Pulvule 240 0.1gmcapsule100 mgoralPharmascience Inc1939-12-312004-03-05Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Seconal Sodiumcapsule100 mg/1oralMarathon Pharmaceuticals, LLC1983-10-03Not applicableUs
Seconal Sodiumcapsule100 mg/1oralValeant Pharmaceuticals North America LLC1983-10-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SeconalNot Available
Brand mixtures
NameLabellerIngredients
Tuinal Pulvule 303Pharmascience Inc
Tuinal Pulvule 304Pharmascience Inc
Salts
Name/CASStructureProperties
Secobarbital Sodium
Thumb
  • InChI Key: AXXJTNXVUHVOJW-UHFFFAOYNA-M
  • Monoisotopic Mass: 260.113687095
  • Average Mass: 260.2647
DBSALT000255
Categories
UNII1P7H87IN75
CAS number76-73-3
WeightAverage: 238.2829
Monoisotopic: 238.131742452
Chemical FormulaC12H18N2O3
InChI KeyInChIKey=KQPKPCNLIDLUMF-UHFFFAOYSA-N
InChI
InChI=1S/C12H18N2O3/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
IUPAC Name
5-(pentan-2-yl)-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione
SMILES
CCCC(C)C1(CC=C)C(=O)NC(=O)NC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the Short-term treatment of intractable insomnia for patients habituated to barbiturates
PharmacodynamicsSecobarbital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Mechanism of actionSecobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationBarbiturates are metabolized primarily by the hepatic microsomal enzyme system, and the metabolic products are excreted in the urine and, less commonly, in the feces.
Half lifeNot Available
ClearanceNot Available
ToxicitySymptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9331
Blood Brain Barrier+0.9762
Caco-2 permeable-0.5792
P-glycoprotein substrateSubstrate0.6367
P-glycoprotein inhibitor INon-inhibitor0.5256
P-glycoprotein inhibitor IINon-inhibitor0.9756
Renal organic cation transporterNon-inhibitor0.911
CYP450 2C9 substrateNon-substrate0.7863
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.736
CYP450 1A2 substrateNon-inhibitor0.8707
CYP450 2C9 inhibitorNon-inhibitor0.7679
CYP450 2D6 inhibitorNon-inhibitor0.9276
CYP450 2C19 inhibitorNon-inhibitor0.7353
CYP450 3A4 inhibitorNon-inhibitor0.8902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9176
Ames testNon AMES toxic0.6131
CarcinogenicityNon-carcinogens0.8977
BiodegradationNot ready biodegradable0.9868
Rat acute toxicity3.0894 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9603
hERG inhibition (predictor II)Non-inhibitor0.9471
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Anabolic inc
  • Barr laboratories inc
  • Everylife
  • Halsey drug co inc
  • Ivax pharmaceuticals inc
  • Kv pharmaceutical co
  • Lannett co inc
  • Parke davis div warner lambert co
  • L perrigo co
  • Purepac pharmaceutical co
  • Valeant pharmaceuticals international
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Wyeth ayerst laboratories
  • Ranbaxy pharmaceuticals inc
  • Elkins sinn div ah robins co inc
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
Capsuleoral100 mg/1
Capsuleoral100 mg
Capsuleoral
Prices
Unit descriptionCostUnit
Seconal 100 mg capsule5.23USD capsule
Seconal sodium 100 mg capsule4.91USD capsule
Seconal sodium 100 mg pulvul0.93USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point100 °CPhysProp
water solubility550 mg/LNot Available
logP1.97HANSCH,C ET AL. (1995)
pKa7.8WOLLWEBER,H (1989)
Predicted Properties
PropertyValueSource
Water Solubility1.21 mg/mLALOGPS
logP2.2ALOGPS
logP2.03ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)8.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.27 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity62.65 m3·mol-1ChemAxon
Polarizability24.33 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.04 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-014i-6900000000-eb3ae85faebb012ef83bView in MoNA
1D NMR1H NMR SpectrumNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05CA06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (48.6 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with 7-Nitroindazole.
AcebutololSecobarbital may increase the hypotensive activities of Acebutolol.
AceclofenacThe metabolism of Aceclofenac can be increased when combined with Secobarbital.
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Secobarbital.
AcepromazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Secobarbital.
AcetazolamideSecobarbital may increase the hypotensive activities of Acetazolamide.
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be increased when combined with Secobarbital.
adipiplonThe risk or severity of adverse effects can be increased when Secobarbital is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Agomelatine.
AldesleukinSecobarbital may increase the hypotensive activities of Aldesleukin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Alfentanil.
AliskirenSecobarbital may increase the hypotensive activities of Aliskiren.
AlmotriptanThe metabolism of Almotriptan can be increased when combined with Secobarbital.
AlosetronThe metabolism of Alosetron can be increased when combined with Secobarbital.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Secobarbital.
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Secobarbital.
AmilorideSecobarbital may increase the hypotensive activities of Amiloride.
AmineptineThe metabolism of Amineptine can be increased when combined with Secobarbital.
AminophenazoneThe metabolism of Aminophenazone can be increased when combined with Secobarbital.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Secobarbital.
AmiodaroneThe metabolism of Amiodarone can be increased when combined with Secobarbital.
AmisulprideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amitriptyline.
AmlodipineSecobarbital may increase the hypotensive activities of Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amobarbital.
AmodiaquineThe metabolism of Amodiaquine can be increased when combined with Secobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amperozide.
AmprenavirThe metabolism of Amprenavir can be increased when combined with Secobarbital.
AmrinoneThe metabolism of Amrinone can be increased when combined with Secobarbital.
Amyl NitriteSecobarbital may increase the hypotensive activities of Amyl Nitrite.
AntipyrineThe metabolism of Antipyrine can be increased when combined with Secobarbital.
ApixabanThe metabolism of Apixaban can be increased when combined with Secobarbital.
ApraclonidineSecobarbital may increase the hypotensive activities of Apraclonidine.
Arachidonic AcidThe metabolism of Arachidonic Acid can be increased when combined with Secobarbital.
ArformoterolThe metabolism of Arformoterol can be increased when combined with Secobarbital.
AripiprazoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with Aripiprazole.
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Secobarbital.
ArtemetherThe metabolism of Artemether can be increased when combined with Secobarbital.
ArticaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Asenapine.
AtazanavirThe metabolism of Atazanavir can be increased when combined with Secobarbital.
AtenololSecobarbital may increase the hypotensive activities of Atenolol.
AtorvastatinThe metabolism of Atorvastatin can be increased when combined with Secobarbital.
AzaperoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Azaperone.
AzelastineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Secobarbital.
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Secobarbital.
Azilsartan medoxomilSecobarbital may increase the hypotensive activities of Azilsartan medoxomil.
AzimilideThe metabolism of Azimilide can be increased when combined with Secobarbital.
BaclofenThe risk or severity of adverse effects can be increased when Secobarbital is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Barbital.
BarnidipineThe metabolism of Barnidipine can be increased when combined with Secobarbital.
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Secobarbital.
BenazeprilSecobarbital may increase the hypotensive activities of Benazepril.
BendroflumethiazideSecobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
BenidipineThe metabolism of Benidipine can be increased when combined with Secobarbital.
BenzocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Secobarbital is combined with Benzyl alcohol.
BepridilThe metabolism of Bepridil can be increased when combined with Secobarbital.
BeraprostThe metabolism of Beraprost can be increased when combined with Secobarbital.
BetaxololSecobarbital may increase the hypotensive activities of Betaxolol.
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Secobarbital.
BexaroteneThe metabolism of Bexarotene can be increased when combined with Secobarbital.
BisoprololSecobarbital may increase the hypotensive activities of Bisoprolol.
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Secobarbital.
BortezomibThe metabolism of Bortezomib can be increased when combined with Secobarbital.
BosentanThe metabolism of Bosentan can be increased when combined with Secobarbital.
BretyliumSecobarbital may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
BrimonidineSecobarbital may increase the hypotensive activities of Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Brotizolam.
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Secobarbital.
BumetanideSecobarbital may increase the hypotensive activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Secobarbital.
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Secobarbital.
BuprenorphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be increased when combined with Secobarbital.
BuspironeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Secobarbital.
ButacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Butorphanol.
CabazitaxelThe metabolism of Cabazitaxel can be increased when combined with Secobarbital.
CabozantinibThe metabolism of Cabozantinib can be increased when combined with Secobarbital.
CaffeineThe metabolism of Caffeine can be increased when combined with Secobarbital.
CanagliflozinSecobarbital may increase the hypotensive activities of Canagliflozin.
CandesartanSecobarbital may increase the hypotensive activities of Candesartan.
CaptoprilSecobarbital may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carisoprodol.
CarteololSecobarbital may increase the hypotensive activities of Carteolol.
CarvedilolSecobarbital may increase the hypotensive activities of Carvedilol.
CelecoxibThe metabolism of Celecoxib can be increased when combined with Secobarbital.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Secobarbital.
CerivastatinThe metabolism of Cerivastatin can be increased when combined with Secobarbital.
CetirizineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Secobarbital can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chloroprocaine.
ChloroquineThe metabolism of Chloroquine can be increased when combined with Secobarbital.
ChlorothiazideSecobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorpromazine.
ChlorpropamideThe metabolism of Chlorpropamide can be increased when combined with Secobarbital.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorprothixene.
ChlorthalidoneSecobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorzoxazone.
CilazaprilSecobarbital may increase the hypotensive activities of Cilazapril.
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Secobarbital.
CinchocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cinchocaine.
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Secobarbital.
CisaprideThe metabolism of Cisapride can be increased when combined with Secobarbital.
CitalopramThe risk or severity of adverse effects can be increased when Secobarbital is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clemastine.
ClevidipineSecobarbital may increase the hypotensive activities of Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clonazepam.
ClonidineSecobarbital may increase the hypotensive activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Secobarbital.
ClopidogrelThe metabolism of Clopidogrel can be increased when combined with Secobarbital.
ClorazepateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Secobarbital.
CocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Secobarbital.
CyclizineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cyclobenzaprine.
CyclophosphamideThe metabolism of Cyclophosphamide can be increased when combined with Secobarbital.
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Secobarbital.
CyproheptadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Cyproheptadine.
DabrafenibThe metabolism of Dabrafenib can be increased when combined with Secobarbital.
DantroleneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dantrolene.
DapagliflozinSecobarbital may increase the hypotensive activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Secobarbital.
DapoxetineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dapoxetine.
DapsoneThe metabolism of Dapsone can be increased when combined with Secobarbital.
DarodipineThe metabolism of Darodipine can be increased when combined with Secobarbital.
DasabuvirThe metabolism of Dasabuvir can be increased when combined with Secobarbital.
deramciclaneThe risk or severity of adverse effects can be increased when Secobarbital is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dexbrompheniramine.
DexmedetomidineSecobarbital may increase the hypotensive activities of Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Secobarbital.
DextromethorphanThe metabolism of Dextromethorphan can be increased when combined with Secobarbital.
DextromoramideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Diazepam.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Secobarbital.
DiclofenamideSecobarbital may increase the hypotensive activities of Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Secobarbital.
DifenoxinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dihydromorphine.
DiltiazemSecobarbital may increase the hypotensive activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dimenhydrinate.
DinutuximabSecobarbital may increase the hypotensive activities of Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Diphenoxylate.
DipyridamoleSecobarbital may increase the hypotensive activities of Dipyridamole.
DolasetronThe metabolism of Dolasetron can be increased when combined with Secobarbital.
DomperidoneThe metabolism of Domperidone can be increased when combined with Secobarbital.
DonepezilThe metabolism of Donepezil can be increased when combined with Secobarbital.
DopamineThe metabolism of Dopamine can be increased when combined with Secobarbital.
DoramectinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Doramectin.
DorzolamideThe metabolism of Dorzolamide can be increased when combined with Secobarbital.
DosulepinThe metabolism of Dosulepin can be increased when combined with Secobarbital.
DotarizineThe metabolism of Dotarizine can be increased when combined with Secobarbital.
DoxazosinSecobarbital may increase the hypotensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Doxepin.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Secobarbital.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
DoxylamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Secobarbital is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
DronabinolThe metabolism of Dronabinol can be increased when combined with Secobarbital.
DroperidolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dyclonine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Secobarbital.
EcgonineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Secobarbital is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Secobarbital is combined with Efavirenz.
EfonidipineThe metabolism of Efonidipine can be increased when combined with Secobarbital.
EletriptanThe metabolism of Eletriptan can be increased when combined with Secobarbital.
EltrombopagThe metabolism of Eltrombopag can be increased when combined with Secobarbital.
EmpagliflozinSecobarbital may increase the hypotensive activities of Empagliflozin.
EnalaprilSecobarbital may increase the hypotensive activities of Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Secobarbital.
EntacaponeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Entacapone.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Secobarbital.
EperisoneThe metabolism of Eperisone can be increased when combined with Secobarbital.
EplerenoneSecobarbital may increase the hypotensive activities of Eplerenone.
EpoprostenolThe metabolism of Epoprostenol can be increased when combined with Secobarbital.
EprosartanSecobarbital may increase the hypotensive activities of Eprosartan.
ErlotinibThe metabolism of Erlotinib can be increased when combined with Secobarbital.
EscitalopramThe risk or severity of adverse effects can be increased when Secobarbital is combined with Escitalopram.
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Secobarbital.
EsmololSecobarbital may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Estazolam.
EstradiolThe metabolism of Estradiol can be increased when combined with Secobarbital.
EstroneThe metabolism of Estrone can be increased when combined with Secobarbital.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Secobarbital.
Etacrynic acidSecobarbital may increase the hypotensive activities of Etacrynic acid.
EthanolSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Secobarbital.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Secobarbital.
EthosuximideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethotoin.
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Secobarbital.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etizolam.
EtodolacThe metabolism of Etodolac can be increased when combined with Secobarbital.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Secobarbital.
EtoperidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etoperidone.
EtoricoxibThe metabolism of Etoricoxib can be increased when combined with Secobarbital.
EtorphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etorphine.
EtravirineThe metabolism of Etravirine can be increased when combined with Secobarbital.
EzogabineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ezogabine.
FelbamateThe serum concentration of Secobarbital can be increased when it is combined with Felbamate.
FelbamateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Felbamate.
FelodipineSecobarbital may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fencamfamine.
FendilineThe metabolism of Fendiline can be increased when combined with Secobarbital.
FenfluramineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fludiazepam.
FlunarizineThe metabolism of Flunarizine can be increased when combined with Secobarbital.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Secobarbital.
FlunitrazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flunitrazepam.
FluorouracilThe metabolism of Fluorouracil can be increased when combined with Secobarbital.
FluoxetineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Flurazepam.
FlurbiprofenThe metabolism of Flurbiprofen can be increased when combined with Secobarbital.
FluspirileneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Fluvastatin can be increased when combined with Secobarbital.
FluvoxamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be increased when combined with Secobarbital.
FosinoprilSecobarbital may increase the hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Fospropofol.
FurosemideSecobarbital may increase the hypotensive activities of Furosemide.
GabapentinThe metabolism of Gabapentin can be increased when combined with Secobarbital.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Secobarbital.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Secobarbital is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Secobarbital is combined with Gamma Hydroxybutyric Acid.
GavestinelThe metabolism of Gavestinel can be increased when combined with Secobarbital.
GliclazideThe metabolism of Gliclazide can be increased when combined with Secobarbital.
GlimepirideThe metabolism of Glimepiride can be increased when combined with Secobarbital.
GlipizideThe metabolism of Glipizide can be increased when combined with Secobarbital.
GlutethimideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Glutethimide.
GlyburideThe metabolism of Glyburide can be increased when combined with Secobarbital.
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Secobarbital.
GuanfacineSecobarbital may increase the hypotensive activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Secobarbital.
HalazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Halazepam.
HalofantrineThe metabolism of Halofantrine can be increased when combined with Secobarbital.
HaloperidolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Hexobarbital.
Histamine PhosphateThe metabolism of Histamine Phosphate can be increased when combined with Secobarbital.
HydralazineSecobarbital may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideSecobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Hydrocodone.
HydroflumethiazideSecobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Secobarbital.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
HydroxyzineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Hydroxyzine.
IbuprofenThe metabolism of Ibuprofen can be increased when combined with Secobarbital.
IdarubicinThe metabolism of Idarubicin can be increased when combined with Secobarbital.
IfosfamideThe metabolism of Ifosfamide can be increased when combined with Secobarbital.
IloperidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Iloperidone.
ImatinibThe metabolism of Imatinib can be increased when combined with Secobarbital.
ImipramineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Indalpine.
IndapamideSecobarbital may increase the orthostatic hypotensive activities of Indapamide.
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Secobarbital.
indisulamThe metabolism of indisulam can be increased when combined with Secobarbital.
IndomethacinThe metabolism of Indomethacin can be increased when combined with Secobarbital.
IrbesartanSecobarbital may increase the hypotensive activities of Irbesartan.
IsofluraneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Isoflurane.
Isosorbide DinitrateSecobarbital may increase the hypotensive activities of Isosorbide Dinitrate.
Isosorbide MononitrateSecobarbital may increase the hypotensive activities of Isosorbide Mononitrate.
IsoxsuprineSecobarbital may increase the hypotensive activities of Isoxsuprine.
IsradipineSecobarbital may increase the hypotensive activities of Isradipine.
IxazomibThe metabolism of Ixazomib can be increased when combined with Secobarbital.
KetamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ketobemidone.
KetoprofenThe metabolism of Ketoprofen can be increased when combined with Secobarbital.
LabetalolSecobarbital may increase the hypotensive activities of Labetalol.
LacidipineThe metabolism of Lacidipine can be increased when combined with Secobarbital.
LamotrigineThe metabolism of Lamotrigine can be increased when combined with Secobarbital.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Secobarbital.
LansoprazoleThe metabolism of Lansoprazole can be increased when combined with Secobarbital.
LapatinibThe metabolism of Lapatinib can be increased when combined with Secobarbital.
LeflunomideThe metabolism of Leflunomide can be increased when combined with Secobarbital.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Secobarbital.
LesinuradThe metabolism of Lesinurad can be increased when combined with Secobarbital.
LevetiracetamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levetiracetam.
LevobunololSecobarbital may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Levorphanol.
LicofeloneThe metabolism of Licofelone can be increased when combined with Secobarbital.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Secobarbital.
LisinoprilSecobarbital may increase the hypotensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lofentanil.
LoperamideThe metabolism of Loperamide can be increased when combined with Secobarbital.
LoratadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Secobarbital.
LornoxicamThe metabolism of Lornoxicam can be increased when combined with Secobarbital.
LosartanSecobarbital may increase the hypotensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Secobarbital.
Lu AA21004The risk or severity of adverse effects can be increased when Secobarbital is combined with Lu AA21004.
LumiracoxibThe metabolism of Lumiracoxib can be increased when combined with Secobarbital.
LurasidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
Magnesium SulfateThe metabolism of Magnesium Sulfate can be increased when combined with Secobarbital.
ManidipineThe metabolism of Manidipine can be increased when combined with Secobarbital.
MannitolSecobarbital may increase the hypotensive activities of Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Maprotiline.
MecamylamineSecobarbital may increase the hypotensive activities of Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Medetomidine.
Mefenamic acidThe metabolism of Mefenamic acid can be increased when combined with Secobarbital.
MelatoninThe risk or severity of adverse effects can be increased when Secobarbital is combined with Melatonin.
MeloxicamThe metabolism of Meloxicam can be increased when combined with Secobarbital.
MelperoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Melperone.
MephenytoinThe metabolism of Mephenytoin can be increased when combined with Secobarbital.
MepivacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Secobarbital.
MesoridazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Mesoridazine.
MestranolThe metabolism of Mestranol can be increased when combined with Secobarbital.
MetaxaloneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Secobarbital.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methaqualone.
MethazolamideSecobarbital may increase the hypotensive activities of Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methsuximide.
MethyclothiazideSecobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.
MethyldopaSecobarbital may increase the hypotensive activities of Methyldopa.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methylphenobarbital.
MetipranololSecobarbital may increase the hypotensive activities of Metipranolol.
MetolazoneSecobarbital may increase the orthostatic hypotensive activities of Metolazone.
MetoprololSecobarbital may increase the hypotensive activities of Metoprolol.
MetronidazoleThe metabolism of Metronidazole can be increased when combined with Secobarbital.
MetyrosineSecobarbital may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
MibefradilThe metabolism of Mibefradil can be increased when combined with Secobarbital.
MidazolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Midazolam.
MilnacipranThe risk or severity of adverse effects can be increased when Secobarbital is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
MinoxidilSecobarbital may increase the hypotensive activities of Minoxidil.
MirtazapineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Secobarbital.
MoclobemideThe metabolism of Moclobemide can be increased when combined with Secobarbital.
MoexiprilSecobarbital may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Molindone.
MontelukastThe metabolism of Montelukast can be increased when combined with Secobarbital.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Secobarbital.
muraglitazarThe metabolism of muraglitazar can be increased when combined with Secobarbital.
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be increased when combined with Secobarbital.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
NabiloneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nabilone.
NadololSecobarbital may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nalbuphine.
NaloxoneThe metabolism of Naloxone can be increased when combined with Secobarbital.
NaproxenThe metabolism of Naproxen can be increased when combined with Secobarbital.
NateglinideThe metabolism of Nateglinide can be increased when combined with Secobarbital.
NebivololSecobarbital may increase the hypotensive activities of Nebivolol.
NesiritideSecobarbital may increase the hypotensive activities of Nesiritide.
NetupitantThe metabolism of Netupitant can be increased when combined with Secobarbital.
NevirapineThe metabolism of Nevirapine can be increased when combined with Secobarbital.
NicardipineSecobarbital may increase the hypotensive activities of Nicardipine.
NiclosamideThe metabolism of Niclosamide can be increased when combined with Secobarbital.
NicotineThe metabolism of Nicotine can be increased when combined with Secobarbital.
NifedipineSecobarbital may increase the hypotensive activities of Nifedipine.
NiguldipineThe metabolism of Niguldipine can be increased when combined with Secobarbital.
NiludipineThe metabolism of Niludipine can be increased when combined with Secobarbital.
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Secobarbital.
NimesulideThe metabolism of Nimesulide can be increased when combined with Secobarbital.
NimodipineSecobarbital may increase the hypotensive activities of Nimodipine.
NisoldipineSecobarbital may increase the hypotensive activities of Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Secobarbital.
NitroglycerinSecobarbital may increase the hypotensive activities of Nitroglycerin.
NitroprussideSecobarbital may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Olanzapine.
OlmesartanSecobarbital may increase the hypotensive activities of Olmesartan.
OlodaterolThe metabolism of Olodaterol can be increased when combined with Secobarbital.
OlopatadineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Olopatadine.
OmbitasvirThe metabolism of Ombitasvir can be increased when combined with Secobarbital.
OmeprazoleThe metabolism of Omeprazole can be increased when combined with Secobarbital.
OndansetronThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Secobarbital is combined with Opium.
OrphenadrineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Secobarbital.
OsanetantThe risk or severity of adverse effects can be increased when Secobarbital is combined with Osanetant.
OspemifeneThe metabolism of Ospemifene can be increased when combined with Secobarbital.
OxaprozinThe metabolism of Oxaprozin can be increased when combined with Secobarbital.
OxazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxazepam.
OxprenololThe serum concentration of Oxprenolol can be decreased when it is combined with Secobarbital.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Secobarbital.
OxybuprocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxymorphone.
PaclitaxelThe metabolism of Paclitaxel can be increased when combined with Secobarbital.
PaliperidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paliperidone.
PapaverineSecobarbital may increase the hypotensive activities of Papaverine.
ParaldehydeSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Secobarbital.
ParamethadioneThe metabolism of Paramethadione can be increased when combined with Secobarbital.
ParecoxibThe metabolism of Parecoxib can be increased when combined with Secobarbital.
ParoxetineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paroxetine.
PazopanibThe metabolism of Pazopanib can be increased when combined with Secobarbital.
PenbutololSecobarbital may increase the hypotensive activities of Penbutolol.
PentamidineThe metabolism of Pentamidine can be increased when combined with Secobarbital.
PentazocineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Secobarbital.
PerampanelThe risk or severity of adverse effects can be increased when Secobarbital is combined with Perampanel.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Secobarbital.
PerindoprilSecobarbital may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Perphenazine.
PethidineSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Secobarbital.
PhenacetinThe metabolism of Phenacetin can be increased when combined with Secobarbital.
PhenindioneThe metabolism of Phenindione can be increased when combined with Secobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Phenoxyethanol.
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Secobarbital.
PhenylbutazoneThe metabolism of Phenylbutazone can be increased when combined with Secobarbital.
PhenytoinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pimozide.
PinaveriumThe metabolism of Pinaverium can be increased when combined with Secobarbital.
PindololSecobarbital may increase the hypotensive activities of Pindolol.
PioglitazoneThe metabolism of Pioglitazone can be increased when combined with Secobarbital.
PipamperoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pipotiazine.
PiroxicamThe metabolism of Piroxicam can be increased when combined with Secobarbital.
PitavastatinThe metabolism of Pitavastatin can be increased when combined with Secobarbital.
PizotifenThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pizotifen.
PolythiazideSecobarbital may increase the orthostatic hypotensive activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pomalidomide.
PonatinibThe metabolism of Ponatinib can be increased when combined with Secobarbital.
PractololThe serum concentration of Practolol can be decreased when it is combined with Secobarbital.
PramipexoleSecobarbital may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pramocaine.
PrasugrelThe metabolism of Prasugrel can be increased when combined with Secobarbital.
PravastatinThe metabolism of Pravastatin can be increased when combined with Secobarbital.
PrazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prazepam.
PrazosinSecobarbital may increase the hypotensive activities of Prazosin.
PregabalinThe metabolism of Pregabalin can be increased when combined with Secobarbital.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Secobarbital.
PrenylamineThe metabolism of Prenylamine can be increased when combined with Secobarbital.
PrilocaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Secobarbital.
ProcaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prochlorperazine.
ProgesteroneThe metabolism of Progesterone can be increased when combined with Secobarbital.
ProguanilThe metabolism of Proguanil can be increased when combined with Secobarbital.
PromazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Promethazine.
PropacetamolThe metabolism of Propacetamol can be increased when combined with Secobarbital.
ProparacaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Propoxycaine.
PropranololSecobarbital may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Secobarbital is combined with PSD502.
PyridoxineThe metabolism of Secobarbital can be increased when combined with Pyridoxine.
QuazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Quazepam.
QuetiapineSecobarbital may increase the hypotensive activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Secobarbital.
QuinaprilSecobarbital may increase the hypotensive activities of Quinapril.
QuinethazoneSecobarbital may increase the orthostatic hypotensive activities of Quinethazone.
QuinidineThe metabolism of Quinidine can be increased when combined with Secobarbital.
QuinineThe metabolism of Quinine can be increased when combined with Secobarbital.
RamelteonThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ramelteon.
RamiprilSecobarbital may increase the hypotensive activities of Ramipril.
RemifentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Secobarbital.
RepaglinideThe metabolism of Repaglinide can be increased when combined with Secobarbital.
ReserpineSecobarbital may increase the hypotensive activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Secobarbital.
RifampicinThe metabolism of Rifampicin can be increased when combined with Secobarbital.
RiociguatSecobarbital may increase the hypotensive activities of Riociguat.
RisedronateThe metabolism of Risedronate can be increased when combined with Secobarbital.
RisperidoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Risperidone.
RofecoxibThe metabolism of Rofecoxib can be increased when combined with Secobarbital.
RomifidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Romifidine.
RopiniroleSecobarbital may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Secobarbital.
RosiglitazoneThe metabolism of Rosiglitazone can be increased when combined with Secobarbital.
RosuvastatinThe metabolism of Rosuvastatin can be increased when combined with Secobarbital.
RotigotineSecobarbital may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Secobarbital.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Secobarbital is combined with S-Ethylisothiourea.
Salicylic acidThe metabolism of Salicylic acid can be increased when combined with Secobarbital.
ScopolamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Scopolamine.
SelegilineThe metabolism of Selegiline can be increased when combined with Secobarbital.
SelexipagThe metabolism of Selexipag can be increased when combined with Secobarbital.
SeratrodastThe metabolism of Seratrodast can be increased when combined with Secobarbital.
SertindoleThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sevoflurane.
SildenafilThe metabolism of Sildenafil can be increased when combined with Secobarbital.
SimvastatinThe metabolism of Simvastatin can be increased when combined with Secobarbital.
SitagliptinThe metabolism of Sitagliptin can be increased when combined with Secobarbital.
SitaxentanThe metabolism of Sitaxentan can be increased when combined with Secobarbital.
Sodium oxybateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sodium oxybate.
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Secobarbital.
SorafenibThe metabolism of Sorafenib can be increased when combined with Secobarbital.
SotalolSecobarbital may increase the hypotensive activities of Sotalol.
SpironolactoneSecobarbital may increase the hypotensive activities of Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sufentanil.
SulfadiazineThe metabolism of Sulfadiazine can be increased when combined with Secobarbital.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be increased when combined with Secobarbital.
SulfamoxoleThe metabolism of Sulfamoxole can be increased when combined with Secobarbital.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be increased when combined with Secobarbital.
SulfisoxazoleThe metabolism of Sulfisoxazole can be increased when combined with Secobarbital.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Secobarbital.
SuprofenThe metabolism of Suprofen can be increased when combined with Secobarbital.
SuvorexantThe risk or severity of adverse effects can be increased when Secobarbital is combined with Suvorexant.
TamoxifenThe metabolism of Tamoxifen can be increased when combined with Secobarbital.
TapentadolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tasimelteon.
TazaroteneThe metabolism of Tazarotene can be increased when combined with Secobarbital.
TelmisartanSecobarbital may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Secobarbital.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Secobarbital.
TenoxicamThe metabolism of Tenoxicam can be increased when combined with Secobarbital.
TerazosinSecobarbital may increase the hypotensive activities of Terazosin.
TerbinafineThe metabolism of Terbinafine can be increased when combined with Secobarbital.
TerfenadineThe metabolism of Terfenadine can be increased when combined with Secobarbital.
TestosteroneThe metabolism of Testosterone can be increased when combined with Secobarbital.
TetrabenazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tetrodotoxin.
ThalidomideSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Secobarbital.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Secobarbital.
ThiamylalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tiagabine.
TianeptineThe metabolism of Tianeptine can be increased when combined with Secobarbital.
TiletamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tiletamine.
TimololSecobarbital may increase the hypotensive activities of Timolol.
TizanidineSecobarbital may increase the hypotensive activities of Tizanidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Secobarbital.
TolbutamideThe metabolism of Tolbutamide can be increased when combined with Secobarbital.
TolcaponeThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tolcapone.
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Secobarbital.
TolterodineThe metabolism of Tolterodine can be increased when combined with Secobarbital.
TopiramateThe risk or severity of adverse effects can be increased when Secobarbital is combined with Topiramate.
TorasemideSecobarbital may increase the hypotensive activities of Torasemide.
TrabectedinThe metabolism of Trabectedin can be increased when combined with Secobarbital.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Secobarbital.
TrandolaprilSecobarbital may increase the hypotensive activities of Trandolapril.
TranilastThe metabolism of Tranilast can be increased when combined with Secobarbital.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trazodone.
TreprostinilThe serum concentration of Treprostinil can be decreased when it is combined with Secobarbital.
TretinoinThe metabolism of Tretinoin can be increased when combined with Secobarbital.
TriamtereneSecobarbital may increase the hypotensive activities of Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triazolam.
TrichlormethiazideSecobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be increased when combined with Secobarbital.
TrimethoprimThe metabolism of Trimethoprim can be increased when combined with Secobarbital.
TrimipramineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Triprolidine.
TroglitazoneThe metabolism of Troglitazone can be increased when combined with Secobarbital.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Secobarbital.
ValdecoxibThe metabolism of Valdecoxib can be increased when combined with Secobarbital.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Secobarbital.
ValsartanSecobarbital may increase the hypotensive activities of Valsartan.
VenlafaxineThe metabolism of Venlafaxine can be increased when combined with Secobarbital.
VerapamilSecobarbital may increase the hypotensive activities of Verapamil.
VicrivirocThe metabolism of Vicriviroc can be increased when combined with Secobarbital.
VigabatrinThe risk or severity of adverse effects can be increased when Secobarbital is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Vilazodone.
VismodegibThe metabolism of Vismodegib can be increased when combined with Secobarbital.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Secobarbital.
VortioxetineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Vortioxetine.
WarfarinThe metabolism of Warfarin can be increased when combined with Secobarbital.
XimelagatranThe metabolism of Ximelagatran can be increased when combined with Secobarbital.
XylazineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Xylazine.
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Secobarbital.
ZafirlukastThe metabolism of Zafirlukast can be increased when combined with Secobarbital.
ZalcitabineThe metabolism of Zalcitabine can be increased when combined with Secobarbital.
ZaleplonThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zaleplon.
ZaltoprofenThe metabolism of Zaltoprofen can be increased when combined with Secobarbital.
ZiconotideThe metabolism of Ziconotide can be increased when combined with Secobarbital.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Secobarbital.
ZidovudineThe metabolism of Zidovudine can be increased when combined with Secobarbital.
ZileutonThe metabolism of Zileuton can be increased when combined with Secobarbital.
ZimelidineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Secobarbital.
ZolazepamThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Secobarbital is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  5. Peters JA, Kirkness EF, Callachan H, Lambert JJ, Turner AJ: Modulation of the GABAA receptor by depressant barbiturates and pregnane steroids. Br J Pharmacol. 1988 Aug;94(4):1257-69. [PubMed:2850060 ]
  6. Miller LG, Deutsch SI, Greenblatt DJ, Paul SM, Shader RI: Acute barbiturate administration increases benzodiazepine receptor binding in vivo. Psychopharmacology (Berl). 1988;96(3):385-90. [PubMed:2906155 ]
  7. Kirkness EF, Turner AJ: The gamma-aminobutyrate/benzodiazepine receptor from pig brain. Purification and characterization of the receptor complex from cerebral cortex and cerebellum. Biochem J. 1986 Jan 1;233(1):265-70. [PubMed:3006661 ]
  8. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  9. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  10. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ligand-gated ion channel activity
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.
Gene Name:
CHRNA4
Uniprot ID:
P43681
Molecular Weight:
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Toxic substance binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is blocked by alpha-bungarotoxin.
Gene Name:
CHRNA7
Uniprot ID:
P36544
Molecular Weight:
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797 ]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Ionotropic glutamate receptor activity
Specific Function:
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and t...
Gene Name:
GRIA2
Uniprot ID:
P42262
Molecular Weight:
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Kainate selective glutamate receptor activity
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIK2
Uniprot ID:
Q13002
Molecular Weight:
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
Components:
NameUniProt IDDetails
Glutamate receptor ionotropic, NMDA 1Q05586 Details
Glutamate receptor ionotropic, NMDA 2AQ12879 Details
Glutamate receptor ionotropic, NMDA 2BQ13224 Details
Glutamate receptor ionotropic, NMDA 2CQ14957 Details
Glutamate receptor ionotropic, NMDA 2DO15399 Details
Glutamate receptor ionotropic, NMDA 3AQ8TCU5 Details
Glutamate receptor ionotropic, NMDA 3BO60391 Details
References
  1. Daniell LC: Effect of anesthetic and convulsant barbiturates on N-methyl-D-aspartate receptor-mediated calcium flux in brain membrane vesicles. Pharmacology. 1994 Nov;49(5):296-307. [PubMed:7862741 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Visser LE, van Schaik RH, Jan Danser AH, Hofman A, Witteman JC, van Duijn CM, Uitterlinden AG, Pols HA, Stricker BH: The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet Genomics. 2007 Jul;17(7):473-9. [PubMed:17558303 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Visser LE, van Schaik RH, Jan Danser AH, Hofman A, Witteman JC, van Duijn CM, Uitterlinden AG, Pols HA, Stricker BH: The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet Genomics. 2007 Jul;17(7):473-9. [PubMed:17558303 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Sakuma T, Ohtake M, Katsurayama Y, Jarukamjorn K, Nemoto N: Induction of CYP1A2 by phenobarbital in the livers of aryl hydrocarbon-responsive and -nonresponsive mice. Drug Metab Dispos. 1999 Mar;27(3):379-84. [PubMed:10064569 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23